Neuropsychiatric disorders during intranasal corticosteroid therapy

Annals of Allergy, Asthma and Immunology

Volumn 101, Issue 3, 2008, Pages 333-334

  Mansfield, Lyndon E ^a  

^a Western Sky Medical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; SODIUM METABISULFITE;

BEHAVIOR; BRONCHOSPASM; COMPARATIVE STUDY; CONVULSION; CORTICOSTEROID THERAPY; FOLLOW UP; HUMAN; MIGRAINE; ODOR; PATIENT COUNSELING; PHYSICAL CHEMISTRY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPATHY; SHORT SURVEY;

EID: 51649130927     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60500-5     Document Type: Article

References (5)

1. Pokladnikova J, Meyboom RHB, Vlcek J, Edwards RI. Intranasally administered corticosteroids and neuropsychiatric disturbances: a review of the International Pharmacovigilance Programme of the World Health Organization. Ann Allergy Asthma Immunol. 2008;101:67-73.
2. Witek TJ Jr, Schachter EN. Detection of sulfur dioxide in bronchodilator aerosols. Chest. 1984;86: 592-594.
3. Meltzer E. Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2007;98:12-21.
4. Wober C, Brannath W, Schmidt K, et al. Prospective analysis of factors related to migraine attacks: the PAMINA study. Cephalalgia. 2007;27:304-314.
5. Staudemeyer H, Kramer RE. Psychogenic chemical sensitivity: pseudoseizures elicited by provocation challenges with fragrances. J Psychosom Res. 1999;47:185-190.